Stan Smith Purchases 25,000 Shares of MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Stan Smith bought 25,000 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The stock was purchased at an average price of $1.87 per share, for a total transaction of $46,750.00. Following the completion of the transaction, the director now directly owns 1,130,060 shares of the company’s stock, valued at $2,113,212.20. This represents a 2.26 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website.

MAIA Biotechnology Trading Down 0.5 %

NYSEAMERICAN:MAIA opened at $2.00 on Monday. The stock has a market capitalization of $50.66 million, a P/E ratio of -1.45 and a beta of 0.14. MAIA Biotechnology, Inc. has a 12 month low of $0.85 and a 12 month high of $5.99.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.21. On average, equities research analysts anticipate that MAIA Biotechnology, Inc. will post -1.3 EPS for the current year.

Institutional Investors Weigh In On MAIA Biotechnology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new stake in MAIA Biotechnology during the third quarter valued at approximately $31,000. Ground Swell Capital LLC bought a new position in shares of MAIA Biotechnology during the second quarter valued at approximately $56,000. Finally, Geode Capital Management LLC grew its stake in shares of MAIA Biotechnology by 22.9% during the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after buying an additional 35,821 shares during the last quarter. 5.65% of the stock is currently owned by hedge funds and other institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.